Haisco Pharmaceutical Group announced that its subsidiary Liaoning Haisco Pharmaceutical Co., Ltd. received the "Acceptance Letter" issued by the National Medical Products Administration on September 23, 2024. This acceptance is for the application for marketing approval of HSK 0.0215 million injection for the new indication of moderate to severe pruritus related to chronic kidney disease in adult maintenance hemodialysis patients.
海思科：HSK2.15万注射液新适应症获受理
Haisco Pharmaceutical Group: HSK 0.0215 million injection new indication accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.